Genenta Science S.p.A.
GNTA evidence brief
What we can confirm
- Market Cap:
- $40.1M
What it means
What to watch
Prepared research question
What matters most for GNTA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GNTA
Genenta Science S.p.A. (GNTA) is a publicly traded Italian biotechnology company developing autologous ex-vivo gene therapies for solid tumors, with its lead candidate Temferon in Phase 1/2a testing for glioblastoma.
Key risk: Limited clinical data
Market Cap
$40.1M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Tracking 2 clinical trials for Genenta Science S.p.A..
Genenta Science S.p.A. (GNTA) is a publicly traded Italian biotechnology company developing autologous ex-vivo gene therapies for solid tumors, with its lead candidate Temferon in Phase 1/2a testing for glioblastoma.
- Lead product candidate Temferon is a cell therapy for glioblastoma patients with an unmethylated MGMT promoter; Phase 1 dose-escalation portion completed and generally well tolerated [sec · filed 2026-04-01].
- The company holds worldwide commercial rights to Temferon (trademark rights limited to U.S. and Europe) for GBM, HCC, and ICC, with exclusive option rights to license additional programs from OSR [sec · filed 2024-03-29].
- Management team includes executives involved in the development of Strimvelis, the first ex-vivo approved gene therapy, and Ethical Oncology Science (acquired for over $400 million) [sec · filed 2025-03-28].
- Manufacturing for Temferon is conducted at AGC Biologics facility in Bresso, Italy, with potential scale-up at AGC's Longmont, Colorado facility [sec · filed 2025-03-28].
- The company expects to continue incurring significant expenses and operating losses for the foreseeable future as it advances R&D and seeks regulatory approval [sec · filed 2026-04-01].
What works
- Management has a proven track record in gene therapy, including the development of Strimvelis, the first ex-vivo approved gene therapy [sec · filed 2025-03-28].
- Temferon was generally well tolerated in the Phase 1 dose-escalation portion, with exploratory analyses suggesting potential biological activity [sec · filed 2026-04-01].
- The company has exclusive option rights to license platform improvements and second-generation technology from OSR, providing a pathway for pipeline expansion [sec · filed 2024-03-29].
What to weigh
- Temferon's exploratory findings are derived from a limited patient population and are not sufficient for definitive conclusions [sec · filed 2026-04-01].
- The company expects to continue incurring significant expenses and operating losses for the foreseeable future, with expenses likely to increase as trials expand [sec · filed 2026-04-01].
- The pipeline is narrow, with Temferon as the only clinical-stage candidate and other programs still in preclinical development [sec · filed 2025-03-28].
From the filings
Quoted directly from source documents.
Temferon Phase 1 dose-escalation completed and generally well tolerated
“The Phase 1 portion of the TEM-GBM Phase 1/2a study, which administered escalating doses of Temferon to glioblastoma patients with an unmethylated MGMT promoter following radiotherapy, has been completed. Preliminary observations from the dose-escalation phase indicated that Temferon was generally well tolerated.”
SEC filings · April 1, 2026
Management team includes developers of Strimvelis and Ethical Oncology Science
“members of our management team have been involved in the successful development of Ethical Oncology Science, which was acquired in 2013 for over $400 million, and Strimvelis the first ever ex-vivo approved gene therapy product that was developed under the guidance of Dr. Carlo Russo, our Chief Medical Officer and Head of Development”
SEC filings · March 28, 2025
Company expects continued significant expenses and operating losses
“We expect to continue to incur significant expenses and operating losses for the foreseeable future.”
SEC filings · April 1, 2026
Risks & what to watch (3)›
Key risks
- Limited clinical data — Temferon's exploratory findings are from a small patient population and are not sufficient for definitive conclusions [sec · filed 2026-04-01].
- Narrow pipeline — Only one clinical-stage candidate (Temferon); all other programs are preclinical [sec · filed 2025-03-28].
- Sustained operating losses — Company expects significant expenses and losses to continue and increase as R&D advances [sec · filed 2026-04-01].
What to watch
- Initiation of a Phase 2a portion of the TEM-GBM study and any updates on patient enrollment or safety [sec · filed 2026-04-01].
- Progress of preclinical programs and any new option rights exercised from OSR or SR-Tiget [sec · filed 2025-03-28].
- Regulatory interactions regarding registration studies for Temferon in the U.S. and Europe [sec · filed 2026-04-01].
- Financial runway and cash position updates in future SEC filings [sec · filed 2026-04-01].
Sources: SEC filings · Generated September 25, 2026 · How we verify sources →
Run Genenta Science S.p.A. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Genenta Science S.p.A. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
11
Total value held
$696K
| Holder | Shares | Value |
|---|---|---|
| eurizon capital sgr s.p.a. | 360,000 | $242K |
| allianz se | 234,050 | $157K |
| alti global, inc. | 200,288 | $135K |
| smartharvest portfolios, llc | 134,447 | $90K |
| independent advisor alliance | 37,036 | $25K |
| xtx topco ltd | 24,527 | $16K |
| morgan stanley | 15,420 | $10K |
| gamma investing llc | 14,288 | $10K |
| simplicity wealth,llc | 12,211 | $8K |
| ubs group ag | 3,107 | $2K |
Showing top 10 of 11 institutional holders of Genenta Science S.p.A.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 0.1%
- Days to cover
- 0.3
- Shares short
- 13,319
- Daily short volume (Oct 12, 2026)
- 36.2%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GNTA short interestFrequently asked questions
What is the AI investment thesis for Genenta Science S.p.A.?
Genenta Science S.p.A. (GNTA) is a publicly traded Italian biotechnology company developing autologous ex-vivo gene therapies for solid tumors, with its lead candidate Temferon in Phase 1/2a testing for glioblastoma.
Who is the CEO of Genenta Science S.p.A.?
Mr. Pierluigi Paracchi is the chief executive officer of Genenta Science S.p.A. (GNTA).
Where is Genenta Science S.p.A. headquartered?
Genenta Science S.p.A. (GNTA) is headquartered in Milan, MI, Italy.
What therapeutic areas does Genenta Science S.p.A. focus on?
Genenta Science S.p.A. develops therapies across Oncology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.